Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A 15 amino acid peptide from near the carboxy terminus of human KAI1.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||20 ug/ml|
|Immunofluorescence (IF)||20 ug/ml|
|Immunohistochemistry (IHC)||2.5 ug/ml|
|Western Blot (WB)||0.5-1 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control is A549 cell lysate.
PA5-20356 can be used with blocking peptide PEP-0476.
KAI1 was initially identified from a T-cell activation study as a four-transmembrane protein that plays an accessory role in T-cell activation, and was later determined to act as a cancer metastasis suppressor gene. This protein is ubiquitously expressed at moderate to high levels in most tissues, but its expression is downregulated during tumor progression. The loss of KAI1 and p53 is associated with poor survival for prostate and other cancer patients. Recently, KAI1 was found to interact with DARC, the Duffy antigen for chemokines using a yeast two hybrid screen. It is thought that tumor cells dislodged from the primary tumor and expressing KAI1 interact with DARC proteins expressed on vascular cells, transmitting a senescent signal to the tumor cells, while tumor cells that have lost KAI1 expression can proliferate and potentially give rise to metastases. At least two isoforms of KAI1 are known to exist.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
4F9; C33; C33 antigen; CD82 antigen; CD82 antigen (R2 leukocyte antigen antigen detected by monoclonal and antibody IA4)); CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4)); GR15; inducible membrane protein R2; KAI1; Kangai 1 (suppression of tumerigenicity 6 prostate) CD82 antigen; kangai 1 (suppression of tumorigenicity 6), prostate; kangai 1 (suppression of tumorigenicity 6, prostate); Kangai 1 (suppression of tumorigenicity 6, prostate; CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4)); metastasis suppressor Kangai-1; metastasis suppressor Kangai-1 homolog; R2; SAR2; ST6; tetraspanin-27; tspan-27; TSPAN27
4F9; AA682076; AL023070; C33; CD82; GR15; IA4; KAI1; R2; SAR2; ST6; TSPAN27